Artwork

Flot.bio์—์„œ ์ œ๊ณตํ•˜๋Š” ์ฝ˜ํ…์ธ ์ž…๋‹ˆ๋‹ค. ์—ํ”ผ์†Œ๋“œ, ๊ทธ๋ž˜ํ”ฝ, ํŒŸ์บ์ŠคํŠธ ์„ค๋ช…์„ ํฌํ•จํ•œ ๋ชจ๋“  ํŒŸ์บ์ŠคํŠธ ์ฝ˜ํ…์ธ ๋Š” Flot.bio ๋˜๋Š” ํ•ด๋‹น ํŒŸ์บ์ŠคํŠธ ํ”Œ๋žซํผ ํŒŒํŠธ๋„ˆ๊ฐ€ ์ง์ ‘ ์—…๋กœ๋“œํ•˜๊ณ  ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ˆ„๊ตฐ๊ฐ€๊ฐ€ ๊ท€ํ•˜์˜ ํ—ˆ๋ฝ ์—†์ด ๊ท€ํ•˜์˜ ์ €์ž‘๋ฌผ์„ ์‚ฌ์šฉํ•˜๊ณ  ์žˆ๋‹ค๊ณ  ์ƒ๊ฐ๋˜๋Š” ๊ฒฝ์šฐ ์—ฌ๊ธฐ์— ์„ค๋ช…๋œ ์ ˆ์ฐจ๋ฅผ ๋”ฐ๋ฅด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค https://ko.player.fm/legal.
Player FM -ํŒŸ ์บ์ŠคํŠธ ์•ฑ
Player FM ์•ฑ์œผ๋กœ ์˜คํ”„๋ผ์ธ์œผ๋กœ ์ „ํ™˜ํ•˜์„ธ์š”!

Dominik Schumacher, Tubulis ๐Ÿ‡ฉ๐Ÿ‡ช | Founder-led ADC Biotech โญ๏ธ | E19

1:08:38
 
๊ณต์œ 
 

Manage episode 428981397 series 3470295
Flot.bio์—์„œ ์ œ๊ณตํ•˜๋Š” ์ฝ˜ํ…์ธ ์ž…๋‹ˆ๋‹ค. ์—ํ”ผ์†Œ๋“œ, ๊ทธ๋ž˜ํ”ฝ, ํŒŸ์บ์ŠคํŠธ ์„ค๋ช…์„ ํฌํ•จํ•œ ๋ชจ๋“  ํŒŸ์บ์ŠคํŠธ ์ฝ˜ํ…์ธ ๋Š” Flot.bio ๋˜๋Š” ํ•ด๋‹น ํŒŸ์บ์ŠคํŠธ ํ”Œ๋žซํผ ํŒŒํŠธ๋„ˆ๊ฐ€ ์ง์ ‘ ์—…๋กœ๋“œํ•˜๊ณ  ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ˆ„๊ตฐ๊ฐ€๊ฐ€ ๊ท€ํ•˜์˜ ํ—ˆ๋ฝ ์—†์ด ๊ท€ํ•˜์˜ ์ €์ž‘๋ฌผ์„ ์‚ฌ์šฉํ•˜๊ณ  ์žˆ๋‹ค๊ณ  ์ƒ๊ฐ๋˜๋Š” ๊ฒฝ์šฐ ์—ฌ๊ธฐ์— ์„ค๋ช…๋œ ์ ˆ์ฐจ๋ฅผ ๋”ฐ๋ฅด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค https://ko.player.fm/legal.

Weโ€™re in Munich ๐Ÿ‡ฉ๐Ÿ‡ช with a โ€œtrueโ€ biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis. We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success. ๐Ÿ”— LINKS MENTIONED - https://curie.bio/ - https://curie.bio - Tubulis Closes Upsized โ‚ฌ128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline - https://tubulis.com/news/tubulis-closes-upsized-e128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline/ - BioSpace - Next wave of ADCs - https://www.biospace.com/article/the-next-wave-of-adcs-could-treat-evasive-solid-tumors-/ - BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival - https://www.fiercebiotech.com/biotech/bms-axes-eisai-adc-pact-3-years-after-paying-650m-would-be-elahere-rival - Merckโ€™s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - https://www.biospace.com/article/merck-s-adc-pact-with-daiichi-hits-regulatory-setback-with-fda-rejection/ - ADC Space is too crowded? - https://drive.google.com/file/d/1oA23bidvd2G-z2lnAkPLAMZgl1RXLtr9/view?usp=sharing - Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio ($1.8B cash) - https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition - BIO-Europe Spring 2019: Newcomer Tubulis tackles ADC technology shortcomings - https://www.youtube.com/watch?v=wwr5KMypBHs - Top 20 Healthcare Specialist Investors - https://drive.google.com/file/d/1r4IwIKvuVUYQaqCZnpm4DtEYyy3LIT7h/view?usp=sharing ๐Ÿ“œ TRANSCRIPT Read the full transcript here: https://flot.bio/episode/dominik-schumacher-tubulis/ ๐Ÿ’ธ DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme โญ๏ธ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! ๐Ÿซถ FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio ๐Ÿ™ LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ๐ŸŽ™๏ธ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. โฐ TIMESTAMPS [00:00:00] Intro [00:01:44] Entrepreneurial biotech family [00:08:46] Market validation [00:14:32] Why Munich [00:17:33] Founder-led biotechs [00:25:20] Balancing 3 kids [00:29:31] Tubulis & ADCs [00:38:25] ADC space is crowded [00:46:12] Deep Track Capital [00:48:17] Vision for Tubulis [00:52:59] ADC space is hot [00:58:03] Chinese biotech [01:02:53] Luck vs success

  continue reading

20 ์—ํ”ผ์†Œ๋“œ

Artwork
icon๊ณต์œ 
 
Manage episode 428981397 series 3470295
Flot.bio์—์„œ ์ œ๊ณตํ•˜๋Š” ์ฝ˜ํ…์ธ ์ž…๋‹ˆ๋‹ค. ์—ํ”ผ์†Œ๋“œ, ๊ทธ๋ž˜ํ”ฝ, ํŒŸ์บ์ŠคํŠธ ์„ค๋ช…์„ ํฌํ•จํ•œ ๋ชจ๋“  ํŒŸ์บ์ŠคํŠธ ์ฝ˜ํ…์ธ ๋Š” Flot.bio ๋˜๋Š” ํ•ด๋‹น ํŒŸ์บ์ŠคํŠธ ํ”Œ๋žซํผ ํŒŒํŠธ๋„ˆ๊ฐ€ ์ง์ ‘ ์—…๋กœ๋“œํ•˜๊ณ  ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ˆ„๊ตฐ๊ฐ€๊ฐ€ ๊ท€ํ•˜์˜ ํ—ˆ๋ฝ ์—†์ด ๊ท€ํ•˜์˜ ์ €์ž‘๋ฌผ์„ ์‚ฌ์šฉํ•˜๊ณ  ์žˆ๋‹ค๊ณ  ์ƒ๊ฐ๋˜๋Š” ๊ฒฝ์šฐ ์—ฌ๊ธฐ์— ์„ค๋ช…๋œ ์ ˆ์ฐจ๋ฅผ ๋”ฐ๋ฅด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค https://ko.player.fm/legal.

Weโ€™re in Munich ๐Ÿ‡ฉ๐Ÿ‡ช with a โ€œtrueโ€ biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis. We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success. ๐Ÿ”— LINKS MENTIONED - https://curie.bio/ - https://curie.bio - Tubulis Closes Upsized โ‚ฌ128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline - https://tubulis.com/news/tubulis-closes-upsized-e128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline/ - BioSpace - Next wave of ADCs - https://www.biospace.com/article/the-next-wave-of-adcs-could-treat-evasive-solid-tumors-/ - BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival - https://www.fiercebiotech.com/biotech/bms-axes-eisai-adc-pact-3-years-after-paying-650m-would-be-elahere-rival - Merckโ€™s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - https://www.biospace.com/article/merck-s-adc-pact-with-daiichi-hits-regulatory-setback-with-fda-rejection/ - ADC Space is too crowded? - https://drive.google.com/file/d/1oA23bidvd2G-z2lnAkPLAMZgl1RXLtr9/view?usp=sharing - Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio ($1.8B cash) - https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition - BIO-Europe Spring 2019: Newcomer Tubulis tackles ADC technology shortcomings - https://www.youtube.com/watch?v=wwr5KMypBHs - Top 20 Healthcare Specialist Investors - https://drive.google.com/file/d/1r4IwIKvuVUYQaqCZnpm4DtEYyy3LIT7h/view?usp=sharing ๐Ÿ“œ TRANSCRIPT Read the full transcript here: https://flot.bio/episode/dominik-schumacher-tubulis/ ๐Ÿ’ธ DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme โญ๏ธ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! ๐Ÿซถ FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio ๐Ÿ™ LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ๐ŸŽ™๏ธ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. โฐ TIMESTAMPS [00:00:00] Intro [00:01:44] Entrepreneurial biotech family [00:08:46] Market validation [00:14:32] Why Munich [00:17:33] Founder-led biotechs [00:25:20] Balancing 3 kids [00:29:31] Tubulis & ADCs [00:38:25] ADC space is crowded [00:46:12] Deep Track Capital [00:48:17] Vision for Tubulis [00:52:59] ADC space is hot [00:58:03] Chinese biotech [01:02:53] Luck vs success

  continue reading

20 ์—ํ”ผ์†Œ๋“œ

ะฃัั– ะตะฟั–ะทะพะดะธ

×
 
Loading …

ํ”Œ๋ ˆ์ด์–ด FM์— ์˜ค์‹ ๊ฒƒ์„ ํ™˜์˜ํ•ฉ๋‹ˆ๋‹ค!

ํ”Œ๋ ˆ์ด์–ด FM์€ ์›น์—์„œ ๊ณ ํ’ˆ์งˆ ํŒŸ์บ์ŠคํŠธ๋ฅผ ๊ฒ€์ƒ‰ํ•˜์—ฌ ์ง€๊ธˆ ๋ฐ”๋กœ ์ฆ๊ธธ ์ˆ˜ ์žˆ๋„๋ก ํ•ฉ๋‹ˆ๋‹ค. ์ตœ๊ณ ์˜ ํŒŸ์บ์ŠคํŠธ ์•ฑ์ด๋ฉฐ Android, iPhone ๋ฐ ์›น์—์„œ๋„ ์ž‘๋™ํ•ฉ๋‹ˆ๋‹ค. ์žฅ์น˜ ๊ฐ„ ๊ตฌ๋… ๋™๊ธฐํ™”๋ฅผ ์œ„ํ•ด ๊ฐ€์ž…ํ•˜์„ธ์š”.

 

๋น ๋ฅธ ์ฐธ์กฐ ๊ฐ€์ด๋“œ